# China NMPA Drug Inspection - Yabao Pharmaceutical Group Co., Ltd - Mu Xiang Shun Qi Wan

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/yabao-pharmaceutical-group-co-ltd/cd0ba2f5-5fe5-4839-ac85-38205a95f99b/
Source feed: China

> China NMPA drug inspection for Yabao Pharmaceutical Group Co., Ltd published May 24, 2018. Drug: Mu Xiang Shun Qi Wan. The National Medical Products Administration (NMPA) of China issued an announcement on May 24, 2018, detailing non-compl

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 29 of 2018 from the National Medical Products Administration regarding 9 batches of drugs that did not meet the requirements.
- Company Name: Yabao Pharmaceutical Group Co., Ltd
- Publication Date: 2018-05-24
- Drug Name: Mu Xiang Shun Qi Wan
- Inspection Finding: The non-compliant item is the property.
- Action Taken: Relevant drug regulatory authorities have taken control measures such as sealing and seizing, requiring enterprises to suspend sales and use, recall products, and rectify the situation. The National Medical Products Administration has instructed relevant provincial drug regulatory authorities to investigate the aforementioned enterprises and units for illegal activities such as producing and selling counterfeit and substandard drugs in accordance with Articles 73, 74, and 75 of the "Drug Administration Law of the People's Republic of China," and to complete the investigation and handling of the relevant enterprises or units within three months from the date of receiving the inspection report and to publicly disclose the results.
- Summary: The National Medical Products Administration (NMPA) of China issued an announcement on May 24, 2018, detailing non-compliance issues found in nine batches of drugs produced by six companies. Testing conducted by the Shanxi Provincial Institute for Food and Drug Control and the Jilin Provincial Institute for Drug Control identified significant quality deviations. Specifically, seven batches of peppermint from five companies, including Beijing Tongrentang (Bozhou) Pharmaceutical Co., Ltd., Bozhou Baishixin Traditional Chinese Medicine Pieces Co., Ltd., and Bozhou Yonggang Pharmaceutical Pieces Factory Co., Ltd., failed due to issues with appearance, microscopic characteristics, and thin-layer chromatography. Additionally, one batch of Muxiang Shunqi Pills from Yaodu Pharmaceutical Group Co., Ltd. showed appearance defects, and one batch of Notopterygium incisum from Bozhou Baishixin Traditional Chinese Medicine Pieces Co., Ltd. had a non-compliant characteristic chromatogram. In response, regulatory authorities enacted immediate control measures, including sealing and seizing the affected products. The implicated companies were mandated to suspend sales, recall the non-compliant drugs, and implement corrective actions. The NMPA further directed provincial-level drug regulatory authorities to investigate these enterprises for potential violations of Articles 73, 74, and 75 of the *Drug Administration Law of the People's Republic of China*, related to the production and sale of substandard drugs. Investigations are required to be completed within three months, with the findings publicly disclosed, reinforcing the NMPA's commitment to drug quality and public safety.

Company: https://www.globalkeysolutions.net/companies/yabao-pharmaceutical-group-co-ltd/3595b3c6-18cb-473b-ac11-ec2413262dfd/